Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2005
Jurisdiction: Switzerland (Incorporated), listed on NYSE
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company operates through two segments: Alcon United States and Alcon International. It is a majority-owned subsidiary of Nestlé S.A. (approx. 75% ownership).
Key Financial Metrics (Year Ended Dec 31, 2005)
| Metric | 2005 (in millions) | 2004 (in millions) |
|---|---|---|
| Sales (Revenue) | $4,368.5 | $3,913.6 |
| Gross Profit | $3,290.1 | $2,832.0 |
| Gross Margin | 75.3% | 72.4% |
| Operating Income | $1,187.9 | $1,131.8 |
| Net Earnings | $931.0 | $871.8 |
| Diluted EPS | $2.98 | $2.80 |
| Operating Cash Flow | $1,235.0 | $1,047.8 |
| Total Assets | $5,228.2 | $4,468.1 |
| Total Debt | $1,083.4 | $988.0 |
| Cash & Equivalents | $1,457.2 | $1,093.4 |
| Shareholders' Equity | $2,556.1 | $2,187.9 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 11.6% to $4.37 billion. Constant currency growth was 10.5%, driven by volume growth in the U.S., Japan, Germany, and Brazil.
- Product Performance:
- Pharmaceuticals: Sales up 14.6% (13.5% constant currency). Growth driven by Vigamox (anti-infective), Travatan (glaucoma), and Patanol (allergy).
- Surgical: Sales up 11.2% (10.2% constant currency). Intraocular lenses and cataract/vitreoretinal products grew significantly, offset by a 10.5% decline in refractive sales.
- Consumer Eye Care: Sales up 4.9% (3.4% constant currency). Artificial tears grew 20.7%, while contact lens disinfectants declined slightly.
- Unusual Items Impacting 2005 Results:
- Patent Litigation Provision: A $240.0 million provision was recorded in Q4 2005 following an adverse court ruling in a patent infringement lawsuit filed by Advanced Medical Optics, Inc. (AMO) regarding the Infiniti vision system.
- Property Damage: An $8.7 million provision was recorded for fire and explosion damage to facilities in Hemel Hempstead, England.
- Adjusted Performance: Excluding the $248.7 million in provisions, operating income would have increased 26.9% to $1.44 billion (32.9% of sales), and net earnings would have increased 39.9% to $1.14 billion.
Guidance, Outlook, and Risks
- Dividend Outlook: Management expects to declare a dividend of CHF 1.68 per share (approx. $1.29) for 2005 operations, subject to shareholder approval in May 2006.
- Share Repurchases: The board authorized an additional 5 million share repurchase in February 2006. In 2005, the company repurchased 3.7 million shares for $391.9 million.
- Key Risks:
- Intellectual Property: The AMO litigation remains a significant contingency. While the injunction was stayed pending appeal, the company is developing an alternative cassette design.
- Regulatory & Pricing: Pressure from third-party payors (Medicare, managed care) and government price controls in Europe and Japan. Specific concern regarding Medicare reimbursement for New Technology Intraocular Lenses (NTIOL).
- Supply Chain: Reliance on single-source suppliers for active ingredients and single-source manufacturing facilities for key products.
- Currency: Exposure to translation and transaction risks, primarily from the Euro, Japanese Yen, and Swiss Franc.
- Product Pipeline: Focus on launching AcrySof ReSTOR Natural IQ, new glaucoma treatments, and refractive laser systems (LADAR6000).
Investor Verification Checklist
- AMO Litigation Status: Verify the current status of the appeal regarding the $213.9 million judgment and the timeline for the alternative Infiniti cassette design.
- Medicare Reimbursement: Confirm the outcome of the request for NTIOL classification for the AcrySof IQ lens and its impact on cataract procedure margins.
- Dividend Approval: Monitor the May 2006 shareholder meeting for approval of the proposed CHF 1.68 dividend.
- Refractive Market Recovery: Assess whether the decline in refractive sales (equipment and technology fees) stabilizes given the economic sensitivity of elective procedures.
- Self-Insurance Exposure: Review the company's exposure to property and casualty risks given the decision to self-insure most liabilities since 2005.